Ilya Rachman Biography and Net Worth

CEO of Immix Biopharma

Ilya Rachman is the Chief Executive Officer of Immix Biopharma, Inc. Dr. Rachman is a physician/scientist and former clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson.

Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and completed several clinical trials as a Principal Investigator building strong relationships in the clinical research industry.

What is Ilya M. Rachman's net worth?: The estimated net worth of Ilya M. Rachman is at least $9.30 million as of December 10th, 2025. Rachman owns 1,141,683 shares of Immix Biopharma stock worth more than $9,304,716 as of March 27th. This net worth evaluation does not reflect any other investments that Rachman may own. Learn More about Ilya M. Rachman's net worth.
How do I contact Ilya M. Rachman?: The corporate mailing address for Rachman and other Immix Biopharma executives is , , . Immix Biopharma can also be reached via phone at 310-651-8041. Learn More on Ilya M. Rachman's contact information.
Has Ilya M. Rachman been buying or selling shares of Immix Biopharma?: Ilya M. Rachman has not been actively trading shares of Immix Biopharma during the last ninety days. Most recently, on Wednesday, December 10th, Ilya M. Rachman bought 746 shares of Immix Biopharma stock. The stock was acquired at an average cost of $6.67 per share, with a total value of $4,975.82. Following the completion of the transaction, the chief executive officer now directly owns 1,141,683 shares of the company's stock, valued at $7,615,025.61. Learn More on Ilya M. Rachman's trading history.
Who are Immix Biopharma's active insiders?: Immix Biopharma's insider roster includes Jason Hsu (Director), Gabriel Morris (CFO), Carey Ng (Director), and Ilya Rachman (CEO). Learn More on Immix Biopharma's active insiders.
Are insiders buying or selling shares of Immix Biopharma?: In the last twelve months, Immix Biopharma insiders bought shares 6 times. They purchased a total of 11,019 shares worth more than $30,275.04. The most recent insider tranaction occured on December, 10th when CEO Ilya M Rachman bought 746 shares worth more than $4,975.82. Insiders at Immix Biopharma own 55.4% of the company. Learn More about insider trades at Immix Biopharma.
Information on this page was last updated on 12/10/2025.

Ilya M. Rachman Insider Trading History at Immix Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2025	Buy	746	$6.67	$4,975.82	1,141,683
9/17/2025	Buy	2,500	$2.02	$5,050.00	1,140,937
6/18/2025	Buy	2,178	$2.29	$4,987.62	1,138,437
6/7/2024	Buy	2,600	$2.13	$5,538.00	1,136,259
5/14/2024	Buy	4,300	$2.25	$9,675.00	912,000
11/14/2022	Buy	5,200	$1.00	$5,200.00	907,700

Ilya M. Rachman Buying and Selling Activity at Immix Biopharma

Immix Biopharma Company Overview

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Today's Range

Now: $8.15

$8.00

$9.19

50 Day Range

MA: $7.70

$4.60

$11.12

2 Week Range

Now: $8.15

$1.34

$11.61

Volume

750,582 shs

Average Volume

889,096 shs

Market Capitalization

$431.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25